imatinib mesylate has been researched along with Bone Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubost, JJ; Ledoux-Eberst, J; Pezet, D; Soubrier, M; Vaure-Chiffre, J | 1 |
| Alves, P; Bota, S; Constantino, C; Maia, R | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM | 1 |
| Bik To, L; Condina, MR; Dewar, AL; Farrugia, AN; Hughes, TP; Vernon-Roberts, B; Zannettino, AC | 1 |
1 trial(s) available for imatinib mesylate and Bone Diseases
| Article | Year |
|---|---|
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid | 2004 |
4 other study(ies) available for imatinib mesylate and Bone Diseases
| Article | Year |
|---|---|
Imatinib-induced bone oedema mimicking Type 1 complex regional pain syndrome.
Topics: Bone Diseases; Diagnosis, Differential; Edema; Female; Humans; Imatinib Mesylate; Middle Aged; Reflex Sympathetic Dystrophy | 2020 |
Hypereosinophilia and severe bone disease in an African child: an unexpected diagnosis.
Topics: Adrenal Cortex Hormones; Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Bone Diseases; Child, Preschool; Drug Combinations; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Ivermectin; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Rare Diseases; Receptor, Platelet-Derived Growth Factor alpha; Strongyloides stercoralis; Strongyloidiasis; Treatment Outcome | 2019 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Imatinib as a potential antiresorptive therapy for bone disease.
Topics: Animals; Benzamides; Bone Diseases; Bone Resorption; Dose-Response Relationship, Drug; Glycoproteins; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Monocytes; Osteoclasts; Osteoprotegerin; Piperazines; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2006 |